Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 5/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.41 |
| ▸ | CCKAR | P32238 | 3/20 | 0.41 |
| ▸ | CCKBR | P32239 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30974122 | 0.95 | GLO1 (0.43) | PTPN1GLO1BACE1OPRD1EGFR | |
| SCHEMBL29695472 | 0.91 | BACE1 (0.46) | BACE1OPRD1CTSD | |
| SCHEMBL30873780 | 0.90 | GNPAT (0.47) | PTPN1BACE1GNPATCTSD | |
| SCHEMBL30099711 | 0.89 | GLO1 (0.42) | GLO1GNPATPTGS1GSTK1 | |
| SCHEMBL29591098 | 0.89 | ENPEP (0.46) | PTPN1BACE1GNPATCTSD | |
| SCHEMBL29772105 | 0.88 | BACE1 (0.42) | BACE1OPRD1EGFRCTSDOPRM1 | |
| SCHEMBL29630690 | 0.88 | FOLH1 (0.46) | PTPN1BACE1CTSD | |
| SCHEMBL6049343 | 0.88 | BACE1 (0.48) | PTPN1GLO1BACE1EGFRCTSD | |
| SCHEMBL6049342 | 0.88 | BACE1 (0.48) | PTPN1GLO1BACE1EGFRCTSD | |
| SCHEMBL30099595 | 0.87 | GLO1 (0.42) | PTPN1GLO1OPRD1GNPATPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267193-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | Ludwig-Maximilians-Universität München (DE) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136555-A9 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | TUBB6, GALNT10, TUBB | PTPN1 734/4885GLO1 2293/4885BACE1 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.